ADMA Biologics, Inc. (NASDAQ: ADMA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 13.75 | EPS (ttm) | 0.72 | Insider Own | 18.53% | Shs Outstand | 231.77M | Perf Week | 17.02% |
| Market Cap | 2.29B | Forward P/E | 10.50 | EPS next Y | 0.94 | Insider Trans | -0.02% | Shs Float | 226.72M | Perf Month | 6.80% |
| Enterprise Value | 2.36B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 10.60% | Perf Quarter | 16.88% |
| Income | 171.63M | P/S | 4.48 | EPS this Y | 17.21% | Inst Trans | - | Short Ratio | 4.87 | Perf Half Y | -37.89% |
| Sales | 512.28M | P/B | 5.54 | EPS next Y | 18.26% | ROA | 24.69% | Short Interest | 24.03M | Perf YTD | -45.72% |
| Book/sh | - | P/C | 11.59 | EPS next 5Y | 21.96% | ROE | 39.59% | 52W High | 20.13 -51.61% | Perf Year | -46.60% |
| Cash/sh | - | P/FCF | 13.33 | EPS past 3/5Y | - | ROIC | 27.55% | 52W Low | 7.09 37.31% | Perf 3Y | 144.44% |
| Dividend Est. | - | EV/EBITDA | 10.06 | Sales past 3/5Y | 49.06% 64.76% | Gross Margin | 64.71% | Volatility | 4.75% 3.50% | Perf 5Y | 538.71% |
| Dividend TTM | - | EV/Sales | 4.61 | EPS Y/Y TTM | -16.05% | Oper. Margin | 42.26% | ATR (14) | 0.38 | Perf 10Y | 35.43% |
| Dividend Ex-Date | - | Quick Ratio | 3.81 | Sales Y/Y TTM | 19.48% | Profit Margin | 32.98% | RSI (14) | 68.41 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.97 | EPS Q/Q | 35.71% | SMA20 | 12.26% | Beta | 0.80 | Target Price | 18.67 |
| Payout | 0.00% | Debt/Eq | 0.50 | Sales Q/Q | -0.87% | SMA50 | 15.09% | Rel Volume | 0.94 | Prev Close | 9.90 |
| Employees | 647 | LT Debt/Eq | 0.16 | Earnings | Nov 04 | SMA200 | -25.05% | Avg Volume | 3.52M | Price | 9.74 |
| IPO Date | Oct 17, 2013 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -1.72% -18.20% | Net Debt/EBITDA | 0.29 | Volume | 3,303,098 | Change | -1.62% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-15-26 | Reiterated | Mizuho | Outperform | $24 → $17 |
| Jun-10-26 | Resumed | Raymond James | Outperform | $21 |
| May-07-26 | Reiterated | Canaccord Genuity | Buy | $21 → $18 |
| Apr-20-26 | Initiated | Canaccord | Buy | $21 |
| Apr-13-26 | Reiterated | Mizuho | Outperform | $14 → $24 |
| Mar-26-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral | |
| Oct-14-24 | Reiterated | HC Wainwright & Co. | Buy | $4.50 → $18 |
| Jun-20-24 | Reiterated | Mizuho | Buy | $6.00 → $14 |
| Jan-03-23 | Reiterated | HC Wainwright & Co. | Buy | $4.00 → $4.50 |
| Nov-10-22 | Reiterated | Mizuho | Buy | $6.00 |
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 511 | 510 | 426 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 181 | 217 | 207 | — | — | — | — | — | — | |
| Gross Profit | 332 | 293 | 220 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 101 | 92 | 74 | — | — | — | — | — | — | |
| Research and Development | 12 | 5 | 2 | — | — | — | — | — | — | |
| Other Operating Expense | 2 | 4 | 5 | — | — | — | — | — | — | |
| Operating Income | 216 | 191 | 139 | — | — | — | — | — | — | |
| Interest Expense | 9 | 7 | 14 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | -2 | 1 | — | — | — | — | — | — | |
| Net Income Before Taxes | 217 | 183 | 126 | — | — | — | — | — | — | |
| Income Taxes | 47 | 36 | -72 | — | — | — | — | — | — | |
| Consolidated Net Income | 168 | 147 | 198 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 168 | 147 | 198 | — | — | — | — | — | — | |
| Net Income | 168 | 147 | 198 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.72 | 0.62 | 0.85 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.72 | 0.62 | 0.85 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.70 | 0.60 | 0.81 | — | — | — | — | — | — | |
| EBITDA | 234 | 198 | 148 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 13.91 | 30.40 | 21.17 | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.35 | 8.51 | 9.38 | — | — | — | — | — | — | |
| Gross Margin | 64.97 | 57.45 | 51.64 | — | — | — | — | — | — | |
| Operating Margin | 42.27 | 37.45 | 32.63 | — | — | — | — | — | — | |
| Net Margin | 32.88 | 28.82 | 46.48 | — | — | — | — | — | — | |
| Shares Outstanding | 228 | 238 | 233 | — | — | — | — | — | — | |
| Market Capitalization | 2,221 | 4,341 | 3,996 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Grossman Jerrold B | Director | May 27 '26 | Buy | 7.91 | 6,400 | 50,624 | 520,284 | May 28 |
| Grossman Jerrold B | Director | May 12 '26 | Buy | 8.01 | 12,500 | 100,125 | 513,884 | May 14 |
| Grossman Jerrold B | Director | May 11 '26 | Buy | 8.01 | 12,500 | 100,125 | 501,384 | May 12 |
| Grossman Adam S | President and CEO | Mar 16 '26 | Sale | 15.16 | 21,000 | 318,360 | 2,112,777 | Mar 17 |
| Grossman Adam S | President and CEO | Mar 16 '26 | Option Exercise | 5.40 | 15,000 | 81,000 | 2,133,777 | Mar 17 |
| Guiheen Lawrence P. | Director | Mar 13 '26 | Option Exercise | 3.66 | 30,000 | 109,800 | 135,520 | Mar 17 |
| Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | Mar 09 '26 | Option Exercise | 3.20 | 10,096 | 32,330 | 476,696 | Mar 10 |
| Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | Mar 09 '26 | Sale | 15.63 | 10,096 | 157,800 | 466,600 | Mar 10 |
| ELMS STEVE | Director | Mar 06 '26 | Buy | 15.39 | 7,000 | 107,730 | 2,045,730 | Mar 09 |
| ELMS STEVE | Director | Mar 05 '26 | Buy | 15.67 | 7,000 | 109,690 | 2,038,730 | Mar 09 |
| Grossman Adam S | President and CEO | Feb 17 '26 | Option Exercise | 5.40 | 15,000 | 81,000 | 2,305,379 | Feb 17 |
| Grossman Adam S | President and CEO | Feb 17 '26 | Sale | 16.08 | 21,000 | 337,680 | 2,284,379 | Feb 17 |
| Grossman Adam S | President and CEO | Dec 15 '25 | Sale | 19.79 | 21,000 | 415,590 | 2,007,850 | Dec 16 |
| Grossman Adam S | President and CEO | Dec 15 '25 | Option Exercise | 5.40 | 15,000 | 81,000 | 2,028,850 | Dec 16 |
| Grossman Adam S | President and CEO | Nov 19 '25 | Sale | 16.00 | 21,000 | 336,000 | 2,013,850 | Nov 21 |